SCHEMBL15052582

SCHEMBL15052582

COc1cc2ncnc(Nc3cccc(O)c3)c2cc1-c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 10/20 1.00
RAF1 P04049 9/20 1.00
RET P07949 5/20 0.77
KDR P35968 5/20 0.77
FGFR1 P11362 2/20 0.77
FLT1 P17948 2/20 0.77
KIF5B P33176 2/20 0.77
CDK2 P24941 1/20 0.77
PIK3R1 P27986 1/20 0.77
EPHB2 P29323 1/20 0.77
TTBK1 Q5TCY1 1/20 0.77
NOD1 Q9Y239 1/20 0.76
EGFR P00533 4/20 0.64
GAK O14976 1/20 0.64
RIPK2 O43353 1/20 0.64
STK10 O94804 1/20 0.64
FLT3 P36888 1/20 0.64
JAK3 P52333 1/20 0.64
AAK1 Q2M2I8 1/20 0.64
Q6ZSR9 Q6ZSR9 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15051582 0.94 BRAF (1.00) BRAFRAF1RETKDRFGFR1
SCHEMBL15051444 0.91 BRAF (1.00) BRAFRAF1RETKDRFGFR1
SCHEMBL1180103 0.87 KDR (1.00) BRAFRAF1RETKDRFGFR1
SCHEMBL29435034 0.87 KDR (1.00) BRAFRAF1RETKDRFGFR1
SCHEMBL30249695 0.87 KDR (1.00) BRAFRAF1RETKDRFGFR1
Hydrochloric Acid SCHEMBL30433676 0.86 NOD1 (1.00) BRAFRAF1RETKDRFGFR1
SCHEMBL15077863 0.85 RAF1 (0.74) BRAFRAF1RETKDRFGFR1
SCHEMBL15077858 0.83 BRAF (0.85) BRAFRAF1RETKDRFGFR1
SCHEMBL15051942 0.80 BRAF (1.00) BRAFRAF1
SCHEMBL15051719 0.80 BRAF (0.83) BRAFRAF1RETKDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785459-B2 Quinazoline compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2014-07-22 US claimed
US-20130165458-A1 QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2013-06-27 US claimed
US-8785459-B2 Quinazoline compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2014-07-22 US disclosed
US-8785459-B2 Quinazoline compounds as kinase inhibitors DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2014-07-22 US disclosed
US-20130165458-A1 QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2013-06-27 US disclosed
US-20130165458-A1 QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165458-A1 QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS CNKSR1, NRAS, HRAS BRAF 8/4885RAF1 10/4885RET 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.